- Home
- AHR vs RYTM Comparison
AHR vs RYTM Comparison
Compare AHR & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AHR
- RYTM
- Stock Information
- Founded
- AHR 2013
- RYTM 2008
- Country
- AHR United States
- RYTM United States
- Employees
- AHR N/A
- RYTM N/A
- Industry
- AHR
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- AHR
- RYTM Health Care
- Exchange
- AHR NYSE
- RYTM Nasdaq
- Market Cap
- AHR 5.2B
- RYTM 4.3B
- IPO Year
- AHR 2024
- RYTM 2017
- Fundamental
- Price
- AHR $36.48
- RYTM $63.62
- Analyst Decision
- AHR Strong Buy
- RYTM Strong Buy
- Analyst Count
- AHR 8
- RYTM 12
- Target Price
- AHR $37.75
- RYTM $77.50
- AVG Volume (30 Days)
- AHR 1.9M
- RYTM 560.2K
- Earning Date
- AHR 08-04-2025
- RYTM 08-05-2025
- Dividend Yield
- AHR 2.72%
- RYTM N/A
- EPS Growth
- AHR N/A
- RYTM N/A
- EPS
- AHR N/A
- RYTM N/A
- Revenue
- AHR $2,104,227,000.00
- RYTM $136,863,000.00
- Revenue This Year
- AHR $8.10
- RYTM $37.56
- Revenue Next Year
- AHR $6.50
- RYTM $74.99
- P/E Ratio
- AHR N/A
- RYTM N/A
- Revenue Growth
- AHR 10.53
- RYTM 48.88
- 52 Week Low
- AHR $14.41
- RYTM $40.46
- 52 Week High
- AHR $36.96
- RYTM $69.89
- Technical
- Relative Strength Index (RSI)
- AHR 57.41
- RYTM 46.09
- Support Level
- AHR $35.46
- RYTM $60.70
- Resistance Level
- AHR $36.83
- RYTM $64.00
- Average True Range (ATR)
- AHR 0.89
- RYTM 2.22
- MACD
- AHR -0.07
- RYTM -0.39
- Stochastic Oscillator
- AHR 46.19
- RYTM 8.11
About AHR AMERICAN HEALTHCARE REIT INC
American Healthcare REIT Inc is a healthcare-focused real estate investment trust. It owns a diversified portfolio of clinical healthcare real estate properties, focusing on medical office buildings, skilled nursing facilities, senior housing, hospitals, and other healthcare-related facilities. It has four reportable business segments: integrated senior health campuses, outpatient medical, triple-net leased properties and SHOP. It generates majority of its revenue through Integrated Senior Health Campuses segment.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.